Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response

被引:0
|
作者
Barbosa, D. [1 ]
Duarte, H. [1 ]
Paula Santos, A. [1 ]
Ferro, J. [1 ]
Prospero, I. [1 ]
Silva, D. [1 ]
Gil-Santos, S. [1 ]
Calheiros, R. [1 ]
Fontao de Castro, S. [1 ]
Ferreira, G. [1 ]
Teixeira, P. [1 ]
Lucena Sampaio, I. [1 ]
机构
[1] Portuguese Inst Oncol, Oporto, Portugal
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OP-472
引用
收藏
页码:S219 / S219
页数:1
相关论文
共 50 条
  • [1] Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
    Prado-Wohlwend, S.
    Bernal-Vergara, J. C.
    Utrera-Costero, A.
    Canon-Sanchez, J. R.
    Agudelo-Cifuentes, M.
    Bello-Arques, P.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (01): : 55 - 65
  • [2] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [3] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    [J]. CANCERS, 2022, 14 (03)
  • [4] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Noémie S. Minczeles
    Eelke M. Bos
    Reinoud C. de Leeuw
    Johan M. Kros
    Mark W. Konijnenberg
    Jacoline E. C. Bromberg
    Wouter W. de Herder
    Clemens M. F. Dirven
    Johannes Hofland
    Tessa Brabander
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1195 - 1204
  • [5] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Minczeles, Noemie S.
    Bos, Eelke M. M.
    de Leeuw, Reinoud C. C.
    Kros, Johan M. M.
    Konijnenberg, Mark W. W.
    Bromberg, Jacoline E. C.
    de Herder, Wouter W. W.
    Dirven, Clemens M. F.
    Hofland, Johannes
    Brabander, Tessa
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (04) : 1195 - 1204
  • [6] Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Mroz, Adrianna
    Kapusta, Waldemar
    Dmochowska, Beata
    Kaminski, Grzegorz
    [J]. NUCLEAR MEDICINE REVIEW, 2023, 26 : 143 - 152
  • [7] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Sejin Ha
    Yong-il Kim
    Jungsu S. Oh
    Changhoon Yoo
    Baek-Yeol Ryoo
    Jin-Sook Ryu
    [J]. EJNMMI Physics, 11
  • [8] Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
    Ha, Sejin
    Kim, Yong-il
    Oh, Jungsu S.
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Ryu, Jin-Sook
    [J]. EJNMMI PHYSICS, 2024, 11 (01)
  • [9] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [10] Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
    Magalhaes, D.
    Sampaio, I. L.
    Ferreira, G.
    Bogalho, P.
    Martins-Branco, D.
    Santos, R.
    Duarte, H.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (03) : 249 - 260